Carleton University

Vamorolone Demonstrates Dual Mechanism as Mineralocorticoid Receptor Antagonist in LIONHEART Study

8 months ago

• Vamorolone (Agamree) showed a statistically significant increase in the urinary sodium/potassium ratio compared to placebo in the LIONHEART study, indicating mineralocorticoid receptor antagonism. • The study reveals vamorolone's dual mechanism as both a mineralocorticoid receptor antagonist and a glucocorticoid receptor agonist, distinguishing it from traditional corticosteroids. • These findings suggest potential cardioprotective benefits of vamorolone for Duchenne muscular dystrophy (DMD) patients, warranting further investigation into long-term cardiac outcomes. • Vamorolone is already FDA-approved for DMD, and ongoing research aims to confirm its benefits in managing cardiac complications, especially when initiated early.